Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 27, 2016
Pharmacy Choice - News - Pharmaceutical Development - October 27, 2016

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/27/16 - Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth [Palestine Chronicle, The]
-Actinium Pharmaceuticals, Inc., a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the appointment of Maria Gomes Nunes, Dr. We are excited to welcome Dr. Nunes and Ms. Chen to the Actinium team, said Kaushik J. Dave, Actiniums Chief Executive Officer.
10/27/16 - amcure Initiates Clinical Study in Patients to Test Novel Approach for Treating Advanced and Metastatic Cancers
EGGENSTEIN-LEOPOLDSHAFEN, Germany amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, today announced the initiation and first patient treated in a Phase I/Ib clinical study of their lead program, AMC303, in cancer patients. The study, which will be initially conducted in Belgium and Spain, is designed to assess t
10/27/16 - BioTrace Medical Announces FDA Clearance of Innovative Temporary Pacing Technology for Transcatheter Aortic Valve Procedures and Other Cardiovascular Applications
BioTrace Medical, Inc. today announced U.S. Food and Drug Administration 510 clearance for the company s Tempo Lead, an innovative temporary pacing lead designed for use in procedures in which temporary pacing is indicated, including transcatheter aortic valve replacement and electrophysiology procedures. Temporary leads are used in more than
10/27/16 - Fulvestrant Demonstrates Progression-Free Survival Advantage in 1st Line Advanced Breast Cancer
By a News Reporter-Staff News Editor at Women's Health Weekly AstraZeneca announced data from the Phase III FALCON trial demonstrating superior median progression-free survival for fulvestrant 500 mg compared to anastrozole 1 mg in the 1st line treatment of postmenopausal women with locally-advanced or metastatic breast cancer, who have not had p
10/27/16 - ICON Further Enhances Clinical Trial Feasibility, Protocol Optimisation and Patient Recruitment Capabilities with TriNetX
ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has further improved its feasibility, protocol optimisation and patient recruitment capabilities through the use of TriNetX.. ICON s ability to recruit patients is also strengthened th
10/27/16 - M Pharmaceutical Inc. Shareholder Update Letter Highlights Acquisitions, Financing, Product Development & Study Results
Vancouver, BC- Mr. Brian Keane, President& Chief Executive Officer of M Pharmaceutical Inc.,, a clinical-stage company developing innovative technologies for obesity and weight management, has issued a comprehensive update letter to shareholders. Dear Shareholders of M Pharmaceutical Inc:. The Company will continue to develop its presence in the in
10/27/16 - Matinas BioPharma Presents Preclinical Data of Orally Administered Encochleated Influenza Vaccine in Murine Model at IDWeek 2016 [UMCI News]
-Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, announced the presentation of positive preclinical data demonstrating its cochleate lipid-crystal nano-particle drug...
10/27/16 - MD Anderson-led study finds ribociclib improves progression-free survival for women with metastatic breast cancer
By a News Reporter-Staff News Editor at Women's Health Weekly Copenhagen, Denmark- In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically improved progression-free survival of post-menopausal women with hormone...
10/27/16 - Novartis breakthrough therapy LEE011 ribociclib plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2-...
By a News Reporter-Staff News Editor at Women's Health Weekly Results from the pivotal Phase III MONALEESA-2 study show LEE011 plus letrozole significantly extended progression-free survival compared to a standard of care, letrozole, as a first-line treatment in postmenopausal women with hormone receptor positive, human epidermal growth factor...
10/27/16 - Paratek Pharmaceuticals, Inc. to Host R&D Day on November 17, 2016 [Moj News Agency (Iran)]
-Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that the Company will host an R&D Day on Thursday, November 17, 2016, from 1:00 p.m. to 3:00 p.m. ET at Lotte Palace Hotel in New York City. Keith Rodvold, Pharm D Un
10/27/16 - Patent Issued for Pyrimidine Hydroxy Amide Compounds as HDAC6 Selective Inhibitors (USPTO 9464073)
By a News Reporter-Staff News Editor at Women's Health Weekly A patent by the inventors Mazitschek, Ralph; van Duzer, John H., filed on February 26, 2015, was published online on October 11, 2016, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. Patent number 9464073 is assigned to Acetylon Pharmaceutic
10/27/16 - Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA axitinib In Advanced Renal Cell Carcinoma RCC
By a News Reporter-Staff News Editor at Women's Health Weekly Pfizer Inc. announced data from an ongoing, investigational Phase 1 b study of INLYTA combined with the checkpoint inhibitor pembrolizumab, a PD-1 inhibitor known as KEYTRUDA and marketed by Merck, known as MSD outside the United States and Canada, in treatment-naive patients wit
10/27/16 - Proposed clinical trial could change game for deadly type of Breast Cancer
Scott County resident Kathleen O'Connor helping research team. University of Kentucky Markey Cancer Center oncology Dr. Edward Romond spent his career at UK treating and studying breast cancer, even leading major Phase 3 clinical trials on the breast cancer drug trastuzumab in the early 2000 s.
10/27/16 - Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout [Khaleej Times (United Arab Emirates)]
-Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that it has dosed the first patient in its Phase 2 clinical trial of SEL-212, the companys lead proprietary immunotherapeutic product candidate for the treatment of chronic gout in patients..
10/26/16 - Abeona Therapeutics Announces Fast Track Designation from FDA for ABO-102 in Sanfilippo Syndrome Type A
"Fast Track designation underscores the importance that the FDA places on developing new treatments for life-threatening disorders, such as MPS IIIA, and reinforces our mandate of accelerating the development of ABO-102 to market," stated Timothy J. Miller, Ph.D., President and CEO of Abeona Therapeutics. This designation is in addition to ABO-102
10/26/16 - Abeona Therapeutics Inc. (NASDAQ:ABEO) Files An 8-K
Abeona Therapeutics Inc. (NASDAQ:ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases,announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for ABO-102,a single intravenous injection of AAV gene therapy for subjects with MPS IIIA (S
10/26/16 - Acasti Pharma Builds Intellectual Property Portfolio with Newly Issued U.S. Patent for CaPre
Acasti Pharma today announced that the United States Patent and Trademark Office issued Acasti a patent directed to a method of treating hypertriglyceridemia by the administration of a concentrated phospholipid composition. "The issuance of this important U.S. patent further protects CaPre as a novel method for treating hypertriglyceridemia, a.
10/26/16 - Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth
Actinium Pharmaceuticals, Inc., a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the appointment of Maria Gomes Nunes, Dr. We are excited to welcome Dr. Nunes and Ms. Chen to the Actinium team, said Kaushik J. Dave, Actinium s Chief Executive Offi
10/26/16 - Aeterna Zentaris Completes Patient Recruitment for Confirmatory Phase 3 Trial of Macrilen?
The proposed tradename is subject to approval by the FDA. Richard Sachse, the Company s Chief Scientific Officer, stated, We are committed to the development of Macrilen? because of the medical need for such a convenient test in the absence of an FDA- approved diagnostic test for AGHD. In addition, it is not an FDA- approved procedure.
10/26/16 - Agilis Biotherapeutics Announces Authorization of Phase IIb Clinical Study of Gene Therapy for AADC Deficiency
AGIL-AADC is an adeno-associated virus vector containing the human gene for the AADC enzyme. Dr. Hwu said, "We are pleased to embark on this important clinical study of AGIL-AADC in an effort to expand the promising safety and efficacy observed in studies to date in which AADC deficiency patients have exhibited persistent improvements in functional
10/26/16 - Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves' Disease
Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that the first patient has been enrolled in the Phase I clinical trial of its novel peptide therapy, ATX-GD-59, for the treatment of Graves' disease. Apitope's ATX-GD-59 has the potential to treat and prevent the prod
10/26/16 - AstraZeneca's experimental drug delays recurrence of ovarian-cancer tumors, study finds []
Oct. 26 AstraZeneca's Lynparza tablets substantially delayed the recurrence of ovarian cancer in women compared with a placebo, according to results of a Phase 3 patient study announced Wednesday. AstraZeneca wants to expand the marketing label to include Lynparza as a maintenance therapy for ovarian cancer. AstraZeneca did not release specific s
10/26/16 - AstraZenecas Lynparza shows significant PFS benefit in ovarian cancer patients [Khaleej Times (United Arab Emirates)]
AstraZeneca said the median PFS in the Lynparza arm of SOLO-2 substantially exceeded that observed in the phase II maintenance study in patients with platinum-sensitive relapsed ovarian cancer. AstraZeneca executive vice president for global medicines development and chief medical officer Sean Bohen said: We will work with regulatory authorities to
10/26/16 - AXIM Biotechnologies, Inc. Secures Funding to Continue Pharmaceutical Clinical Trials Program in Cannabinoid Research and Development for Multiple Indications
AXIM Biotechnologies, Inc., a world leader in cannabinoid research and development, today announced that the Company has secured private funding to continue its pharmaceutical clinical trials program in cannabinoid research and development for multiple indications.. An AXIM Biotech breakthrough invention on pace to be fully registered by th
10/26/16 - Beximco Pharma gets all-clear from FDA to sell another drug in US market [Daily News Egypt]
In the media release, Nazmul Hassan, Managing Director of Beximco Pharmaceuticals, said, "We are delighted to have received our second product approval from the US FDA." Beximco Pharma became the first Bangladeshi pharmaceutical company audited and approved by the US FDA in June 2015, the release said. The company currently has a global footprint i
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement